



PRIOR AUTHORIZATION WITH STEP THERAPY POLICY

- POLICY:** Wakefulness-Promoting Agents – Sunosi Prior Authorization with Step Therapy Policy
- Sunosi® (solriamfetol tablets – Jazz)

REVIEW DATE: 09/20/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with **excessive daytime sleepiness** associated with the following conditions:¹

- **Narcolepsy.**
- **Obstructive sleep apnea (OSA).**

Limitations of Use: Sunosi is not indicated to treat the underlying airway obstruction in OSA.¹ The underlying airway obstruction should be treated (e.g., with continuous positive airway pressure [CPAP]) for at least 1 month prior to initiating Sunosi for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with Sunosi.

Sunosi is a Schedule IV controlled substance.¹

Armodafinil and modafinil are wakefulness-promoting agents with actions similar to sympathomimetic agents (e.g., amphetamine and methylphenidate).^{2,3} They are indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, OSA, or shift work disorder. Armodafinil and modafinil are Schedule IV

controlled substances. Stimulant medications (e.g., amphetamine, methamphetamine, dextroamphetamine, and methylphenidate) are used off-label for the treatment of daytime sleepiness due to narcolepsy and OSA and are mentioned in guidelines.⁴⁻⁷

Two specialized tests, which can be performed in a sleep disorders clinic, are required to establish a diagnosis of narcolepsy.⁸ Polysomnogram (PSG) is an overnight recording of brain and muscle activity, breathing, and eye movements. The multiple sleep latency test assesses daytime sleepiness by measuring how quickly a person falls asleep and whether they enter rapid eye movement (REM) sleep. On the day after PSG, the patient is asked to take five short naps separated by two hours over the course of a day. If an individual falls asleep in < 8 minutes on average over the five naps, this indicates excessive daytime sleepiness. However, patients with narcolepsy also have an abnormally quick start to REM sleep. If REM sleep happens within 15 minutes at least two times out of the five naps and the sleep study the night before, this is likely an abnormality caused by narcolepsy.

Guidelines

Narcolepsy and Cataplexy

The American Academy of Sleep Medicine (AASM) practice parameters for the treatment of central disorders of hypersomnolence were updated in 2021.^{4,5}

- Modafinil, Wakix[®] (pitolisant tablet), Xyrem[®] (sodium oxybate oral solution), and Sunosi are recommended as effective treatments for daytime sleepiness due to narcolepsy and reducing disease severity in adults (Strong Recommendation for each).
- Wakix and Xyrem have also demonstrated efficacy for the treatment of cataplexy in patients with narcolepsy (Strong Recommendation for each).
- Xyrem and armodafinil have Conditional Recommendations for the treatment of narcolepsy, showing efficacy for daytime sleepiness due to narcolepsy and reducing disease severity.
- Dextroamphetamine has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy for excessive daytime sleepiness and cataplexy.
- Methylphenidate has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy in reducing disease severity.
- There was insufficient and inconclusive evidence to make recommendations for l-carnitine, scheduled naps, selegiline, triazolam, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs).
- Modafinil and Xyrem have Conditional Recommendations for the treatment of narcolepsy in pediatric patients.
- A Strong Recommendation should be followed by clinicians under most circumstances. A Conditional Recommendation requires that the clinician use clinical knowledge and experience and strongly consider the individual patient's values and preferences to determine the best course of action.

Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea/Hypoapnea Syndrome

- According to the AASM guideline on medical therapy for OSA (2006), CPAP is the most uniformly effective therapy, and, to date, this is the only intervention for

OSA shown to have favorable impacts on both cardiovascular and neurobehavioral morbidities.^{6,7}

- Modafinil, in patients compliant with nasal CPAP, consistently improved subjective and objective sleepiness, quality of life, and vigilance compared with placebo.
- Sunosi is not addressed in these guidelines.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Sunosi. This Prior Authorization Policy also contains a Step Therapy component. When clinically appropriate, the patient is directed to try one Step 1 Product (modafinil or armodafinil) prior to Sunosi (Step 2). All approvals are provided for the duration noted below.

- **Sunosi® (solriamfetol tablets – Jazz) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

FDA-Approved Indications

- 1. Excessive Daytime Sleepiness Associated with Narcolepsy.** Approve for 1 year if the patient meets the following (A, B, C, D, and E):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has been evaluated using polysomnography and a multiple sleep latency test; AND
 - C)** Diagnosis of narcolepsy has been confirmed, according to the prescriber; AND
 - D)** The medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; AND
 - E)** Patient has tried generic modafinil or generic armodafinil.
Note: An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.
- 2. Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea.** Approve for 1 year if the patient meets the following (A, B, and C):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient meets one of the following (i or ii):
 - i.** Sunosi will be used in conjunction with continuous positive airway pressure (CPAP) therapy; OR
 - ii.** Patient is unable to initiate or tolerate CPAP therapy; AND
 - C)** Patient has tried generic modafinil or generic armodafinil.
Note: An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.

CONDITIONS NOT COVERED

- **Sunosi® (solriamfetol tablets – Jazz)** is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Concomitant Use of Sunosi with an Oxybate Product and/or Wakix (pitolisant tablets). Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea.¹ Oxybate products include Xyrem (sodium oxybate oral solution), Lumryz (sodium oxybate extended-release oral suspension), and Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution).¹⁰⁻¹² These have the same active ingredient (oxybate, a central nervous system depressant) and have not been studied for use in combination or as alternating treatments. Wakix, an antagonist/inverse agonist of the histamine-3 receptor, is indicated for excessive daytime sleepiness and cataplexy in adults with narcolepsy.¹³ Currently, there are no published studies evaluating combination use of these medications.

REFERENCES

1. Sunosi® tablets [prescribing information]. New York, NY: Axsome Therapeutics; June 2023.
2. Provigil® tablets [prescribing information]. North Wales, PA: Cephalon; January 2015.
3. Nuvigil® tablets [prescribing information]. North Wales, PA: Cephalon; February 2017.
4. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med.* 2021;17(9):1881–1893.
5. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med.* 2021;17(9):1895-1945.
6. Veasey SC, Guilleminault C, Strohl KP, et al. Medical therapy for obstructive sleep apnea: a review by the medical therapy for obstructive sleep apnea task force of the standards of practice committee of the American Academy of Sleep Medicine. *Sleep.* 2006;29(8):1036-1044.
7. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. *Sleep.* 2006;29(8):1031-1035.
8. National Institutes of Health. Narcolepsy. National Institute of Neurological Disorders and Stroke. Last reviewed on January 20, 2023. Available at: Narcolepsy | National Institute of Neurological Disorders and Stroke (nih.gov). Accessed on September 18, 2023.
9. Mayo Clinic. Obstructive sleep apnea. Available at: <https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090?p=1>. Accessed on September 18, 2023.
10. Xyrem® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.
11. Lumryz™ extended-release oral suspension [prescribing information]. Chesterfield, MO: Avadel; May 2023.
12. Xywav® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.
13. Wakix® tablets [prescribing information]. Plymouth Meeting, PA: Harmony Biosciences; December 2022.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	09/07/2022

Annual Revision	Conditions Not Covered: Concomitant use of Sunosi with Xyrem (sodium oxybate oral solution), Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution), and/or Wakix (pitolisant tablets) was changed to Concomitant use of Sunosi with an oxybate product and/or Wakix (pitolisant tablets). This change was made due to the availability of a new oxybate product, Lumryz (sodium oxybate extended-release oral suspension). Xyrem, Xywav, and Lumryz are now detailed in the following paragraph.	09/20/2023
-----------------	--	------------

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna